Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials

Background: Tranexamic acid (TXA) has been widely applied to reduce perioperative bleeding. Recently, several studies focused on the administration of TXA in the treatment for with intertrochanteric fracture patients treated with intramedullary fixation. However, the efficacy and safety of TXA in these studies remain controversial. Therefore, we performed this systematic review and meta-analysis to investigate the efficacy and safety of TXA in intertrochanteric fracture patients treated with intramedullary fixation.

Methods: We systematically searched electronic databases, including Cochrane, PubMed, and EMBASE, up to 16 May 2022. The efficacy and safety of TXA was evaluated in four aspects, which were bleeding-related outcomes, non-bleeding-related outcomes, thromboembolic events, and other complications. The outcomes of these studies were extracted and analyzed by RevMan Manager 5.4.

Results: Finally, nine randomized controlled trials, involving nine hundred and seventy-two intertrochanteric fracture patients treated with TXA, were enrolled in this study. In the bleeding-related outcomes, TXA group was significantly lower than the control group in terms of total blood loss (MD = −219.42; 95% CI, −299.80 to −139.03; p < 0.001), intraoperative blood loss (MD = −36.81; 95% CI, −54.21 to −19.41; p < 0.001), hidden blood loss (MD = −189.23; 95% CI, −274.92 to −103.54; p < 0.001), and transfusion rate (RR = 0.64; 95% CI, 0.49 to 0.85; p = 0.002). Moreover, the postoperative hemoglobin on day 3 of the TXA group was significantly higher than that of the control group (MD = 5.75; 95% CI, 1.26 to 10.23; p = 0.01). In the non-bleeding-related outcomes, the length of hospital stays was significantly shorter in the TXA group (MD = −0.67; 95% CI, −1.12 to −0.23; p = 0.003). In terms of thromboembolic events, there was no significant differences between the TXA group and control group in deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke. As for complications and mortality, there was no significant differences between the TXA group and control group in respiratory infection, renal failure, and postoperative mortality within 1 year.

Conclusion: TXA is an effective and safe drug for perioperative bleeding control in intertrochanteric fracture patients treated with intramedullary fixation. However, the long-term efficacy of TXA still needs to be investigated by large-scale multicenter randomized controlled trials.

Level of evidence: II, Systematic review and Meta-analysis.

Systematic Review Registration: https://inplasy.com/, identifier [INPLASY202280027]

Introduction

As a common type of low-violence fractures in the elderly, intertrochanteric fracture is mostly related to osteoporosis (Chen et al., 2021). The incidence of intertrochanteric fractures in the elderly increases rapidly. In addition, intertrochanteric fractures account for almost half of all hip fractures (Cheng et al., 2011; Jiang et al., 2022). The number of hip fractures occurring in the world would rise from 1.66 million in 1990 to 6.26 million by 2050, which would place a heavy burden on the healthcare system (Cooper et al., 1992; Milto et al., 2022). For better functional recovery, early surgical treatment is considered the preferred option for treating intertrochanteric fractures (Dehghan and McKee, 2020). In addition, early operation can reduce the occurrence of perioperative complications and postoperative death (Dehghan and McKee, 2020). According to the fracture type, surgical treatments for intertrochanteric fractures can be divided into internal fixation and joint replacement. Intramedullary fixation systems such as proximal femoral nail autorotation (PFNA), are widely used in treating intertrochanteric fractures. Intramedullary fixation systems have advantages of minimally invasive, simple intraoperative operation, reliable fixation strength, and early ambulation (Tang et al., 2012). Perioperative bleeding is an important factor related to the prognosis of hip fracture patients (Ljungqvist et al., 2017). In addition, the intertrochanteric fractures are often accompanied by massive perioperative blood loss, such as intraoperative bleed loss (IBL) and hidden blood loss (HBL) (Foss and Kehlet, 2006; Vochteloo et al., 2011). Currently, various methods have been utilized to decrease the perioperative blood loss in intertrochanteric fracture patients, which includes blood pressure control, autologous blood transfusion, hemostatic drugs, application of tourniquets, and minimally invasive surgery (Carvalho et al., 2015).

Tranexamic acid (TXA) is a synthetic lysine analogue that acts by inhibiting plasminogen activation (Pabinger et al., 2017). In addition, TXA can effectively reduce the amount of bleeding and has been widely used in spine, shoulder, hip, and knee surgery (Hartland et al., 2021; Ling et al., 2021). Recently, more and more researchers applied TXA to reduce perioperative blood loss in the treatment of intertrochanteric fracture patients undergoing intramedullary fixation surgery (Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022). However, a major limitation of all these trials is the sample size, which may lead to underpowered conclusions. In addition, the efficacy and safety of TXA in intertrochanteric fracture patients treated with intramedullary fixation still remains controversial (Porter et al., 2022). Therefore, we performed this systematic review and meta-analysis to investigate the efficacy and safety of TXA in intertrochanteric fracture patients treated with intramedullary fixation.

Methods

The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines and Quality of Reporting of Meta-analyses (QUORUM) guidelines were followed in this study (Eriksen and Frandsen, 2018). Our study performed a prospective protocol, consisting of objectives, study selection strategies, inclusion criteria, exclusion criteria, statistical analysis, and outcome measures.

Search strategy

Two reviewers independently searched for potentially relevant published by using electronic databases, including Cochrane, PubMed, and EMBASE, from inception to 16 May 2022. The following keywords were used for the search: “Tranexamic Acid,” “TXA,” “Hip Fractures,” “Trochanteric Fractures,” “Intertrochanteric Fractures,” “Subtrochanteric Fractures,” “Fragility Fractures,” This strategy was adapted for each included electronic database, and no specific database filters were applied.

Eligibility criteria

The inclusion criteria for this study were as follows: 1) Population: patients were adults diagnosed with intertrochanteric fractures. The treatment method is intramedullary fixation, include PFNA, Trochanteric femoral nail advanced, Gamma nail, short intramedullary nail, etc. 2) Intervention: patients were treated with TXA. 3) Comparator: patients who received placebo, saline, or blank control. 4) Outcomes: one of the following outcomes was reported. Bleeding-related outcomes consisting of total blood loss (TBL), IBL, HBL, postoperative drainage (POD), blood transfusion rate (BTR), postoperative hemoglobin (Hb) on day 1 or day 3, postoperative hematocrit (Hct) on day 1or day 3. Non-bleeding-related outcomes include the length of hospital stays and surgical time. Thromboembolic events were defined as deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke. Other complications include wound complications (wound hematoma or infection), respiratory infection, and renal failure. And postoperative mortality. 5) Study design: the studies were original, randomized control trials (RCTs) only.

The exclusion criteria for this study were as follows: 1) Publications not in the English language. 2) Retrospective studies, cohort studies, case reports, and case series. 3) Animal studies. 4) Nonoriginal research, such as reviews and technical reports. 5) Single abstracts, expert opinions, and letters to editors. 6) Studies in which the relevant data cannot be extracted, and the original author is contacted without a response. Furthermore, any disagreements were resolved by discussion or consulting with another senior reviewer.

Data extraction

Two reviewers scanned all enrolled studies to extract data independently according to the inclusion and exclusion criteria. The demographic characteristics and surgical information extracted for systematic review were as follows: first author, publication year, country, number of patients, female patients, methods of screening and prophylaxis for thrombosis, the average age of patients, ASA grade, preoperative Hb level, outcome measures, duration of follow-up, fracture types, admission to surgery time, type of anesthesia, surgical procedure, details of the interventions and control, transfusion trigger, postoperative drainage. Means and standard deviations were extracted for outcome measures. We converted medians and interquartile ranges to means and standard deviations for uniform analyses using the methods described by Wan et al. (2014). All data were entered into an electronic spreadsheet. Furthermore, any disagreements were resolved by discussion or consulting with another senior reviewer.

Assessment of methodological quality

According to Cochrane Collaboration for Systematic Reviews, the methodological quality of trials included in this study was evaluated independently by two reviewers (Corbett et al., 2014). The following items were considered: random sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcomes assessment, incomplete outcome data, selective reporting, and other bias. Each item was assessed as “Low risk of bias,” “Unclear risk of bias,” or “High risk of bias.” If the item was reported incorrectly, the judgment was “High risk of bias.” If the item was reported inadequately, the judgment was “Unclear risk of bias.” If the item was reported correctly and adequately, the judgment was “Low risk of bias.” Furthermore, any disagreements were resolved by discussion or consulting with another senior reviewer.

Statistical analysis

The statistical analysis was independently performed with RevMan software (Version 5.4; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020) by two reviewers. The mean difference (MD) between groups of TXA and control was reported with 95% confidence interval (95% CI) and performed to evaluate continuous variables such as TBL. The risk ratio (RR) with 95% CI was performed to evaluate dichotomous outcomes such as BTR. To measure heterogeneity between studies, we used the I² statistic. Furthermore, heterogeneity was accepted, and the randomized-effects model was performed, when I² was>50%. Otherwise, the fixed-effects model was performed. Forest plots were used to graphically represent the difference in outcomes of groups of TXA and control and for all included studies. If p values were <0.05, the results were considered statistically significant. Funnel plot was used to assess publication bias. We only performed analyses of partial outcomes. Because funnel plot may not truly reflect possible publication bias when the included studies are few (Higgins and Green, 2011).

Results

Included studies

In the initial search, a total of two hundred and fifty-two relevant studies were retrieved. After excluding duplicate studies, one hundred and eighty-three studies were screened using their titles and abstracts, and twenty-three studies were left. Through reading the full text, fourteen studies were excluded because of irrelevant to our topic, no relevant data, non-English publications, and ongoing clinical research that has not yet been published. Finally, nine RCTs (Drakos et al., 2016; Tengberg et al., 2016; Lei et al., 2017; Schiavone et al., 2018; Tian et al., 2018; Luo et al., 2019; Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022), including nine hundred and seventy-two participants, met the selection criteria and were enrolled in this study. The flow diagram of this study is shown in Figure 1.

FIGURE 1

FIGURE 1. Flow chart of search and search results.

Study characteristics

The main characteristics and surgical information among the nine enrolled RCTs are shown in Table 1 and Table 2, respectively. Among these enrolled studies, six studies were conducted in China (Lei et al., 2017; Tian et al., 2018; Luo et al., 2019; Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022), each one in Greece (Drakos et al., 2016), Italy (Schiavone et al., 2018) and Denmark (Tengberg et al., 2016). The published years of enrolled RCTs were between 2016 and 2022. Among these included studies, two studies utilized TXA by local administration (Drakos et al., 2016; Yee et al., 2022), and the other studies utilized TXA by intravenous administration (Tengberg et al., 2016; Lei et al., 2017; Schiavone et al., 2018; Tian et al., 2018; Luo et al., 2019; Zhou et al., 2019; Zhang et al., 2022). The fracture type classified by the American Orthopedic/Orthopedic Trauma Association, ranges from 31 A1 to A3. Low molecular weight heparin was used to prevent thromboembolic events in six studies (Drakos et al., 2016; Tengberg et al., 2016; Tian et al., 2018; Luo et al., 2019; Zhou et al., 2019; Zhang et al., 2022). Five studies screened all patients for thromboembolic events such as deep vein thrombosis postoperatively (Lei et al., 2017; Schiavone et al., 2018; Tian et al., 2018; Luo et al., 2019; Zhang et al., 2022), and the other studies performed further imaging and laboratory examination when patients presented with clinical symptoms (Drakos et al., 2016; Tengberg et al., 2016; Zhou et al., 2019; Yee et al., 2022). The procedures for surgery were described in detail in all included studies. Four studies reported that the surgery was performed within 48 h of admission (Drakos et al., 2016; Tengberg et al., 2016; Schiavone et al., 2018; Yee et al., 2022). The implants for intramedullary fixation included PFNA, Trochanteric femoral nail advanced, Gamma nail, and short intramedullary nail. In addition, four studies reported postoperative drainage was performed (Lei et al., 2017; Tian et al., 2018; Zhou et al., 2019; Yee et al., 2022).

TABLE 1

TABLE 1. The main characteristics of the included studies.

TABLE 2

TABLE 2. The surgical information of included studies.

Quality assessment of individual trials

Among these enrolled studies, eight studies were performed with adequate random sequence generation (Drakos et al., 2016; Tengberg et al., 2016; Lei et al., 2017; Tian et al., 2018; Luo et al., 2019; Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022). In addition, three studies were conducted with allocation concealment (Luo et al., 2019; Yee et al., 2022; Zhang et al., 2022), and the other studies were not reported and determined to be unclear (Drakos et al., 2016; Tengberg et al., 2016; Lei et al., 2017; Schiavone et al., 2018; Tian et al., 2018; Zhou et al., 2019). Blinding of participants and personnel was conducted in six studies (Tengberg et al., 2016; Lei et al., 2017; Luo et al., 2019; Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022). Blinding of outcome assessment was reported in six studies (Drakos et al., 2016; Tengberg et al., 2016; Luo et al., 2019; Zhou et al., 2019; Yee et al., 2022; Zhang et al., 2022). In addition, the outcome reports and data of all studies are complete. In addition, no obvious sources of bias in all enrolled trials were identified. Figure 2 shows the risk of bias summary of the included studies. Figure 3 shows the risk of bias graph of the included studies.

FIGURE 2

FIGURE 2. Risk of bias summary: low risk of bias in green; unclear risk of bias in yellow; high risk of bias in red.

FIGURE 3

FIGURE 3. Risk of bias graph: each risk of bias item is presented as the percentage across all the included studies, which indicates the proportion of different levels of risk of bias foreach item.

Meta-analysis of bleeding-related outcomes

All studies reported bleeding-related outcomes, which included four hundred and eighty-three and four hundred and eighty-nine patients in the TXA and control groups, respectively. The results of pooled analyses are shown in Figure 4. The results showed that the TBL of the TXA group was significantly lower than that of the control group (MD = −219.42; 95% CI, −299.80 to −139.03; p < 0.001) (Figure 4A). In addition, the IBL and HBL of the PRP group were significantly lower than that of the control group (MD = −36.81; 95% CI, −54.21 to −19.41; p < 0.001, MD = −189.23; 95% CI, −274.92 to −103.54; p < 0.001) (Figures 4B,C). All enrolled studies reported postoperative BTR. The results showed that the BTR of the TXA group was significantly lower than that of the control group (RR = 0.64; 95% CI, 0.49 to 0.85; p = 0.002) (Figure 4E). And the postoperative Hb on day 3 of the TXA group was significantly higher than that of the control group (MD = 5.75; 95% CI, 1.26 to 10.23; p = 0.01) (Figure 4G). However, there were no significant differences between TXA group and control group in POD (MD = −6.27; 95% CI, −18.73 to 6.19; p = 0.32) (Figure 4D), postoperative Hb on day 1 (MD = 1.56; 95% CI, −23.03 to 26.15; p = 0.90) (Figure 4F), postoperative Hct on day 1 (MD = 1.81; 95% CI, −3.06 to 6.68; p = 0.47) (Figure 4H), postoperative Hct on day 3 (MD = 1.27; 95% CI, −0.32 to 2.86; p = 0.12) (Figure 4I).

FIGURE 4

FIGURE 4. Forest plot showing bleeding-related outcomes of TXA group vs. control group. (A) Total blood loss. (B) Intraoperative blood loss. (C) Hidden blood loss. (D) Postoperative drainage. (E) Blood transfusion rate. (F) Postoperative hemoglobin on day 1. (G) Postoperative hemoglobin on day 3. (H) Postoperative hematocrit on day 1. (I) Postoperative hematocrit on day 3.

Meta-analysis of non–bleeding-related outcomes

Seven studies reported non–bleeding-related outcomes, which included four hundred and three and four hundred and seven patients in the TXA and control groups, respectively. The results of pooled analyses are shown in Figure 5. The results showed that the length of hospital stays of the TXA group were significantly lower than that of the control group (MD = −0.67; 95% CI, −1.12 to −0.23; p = 0.003) (Figure 5A). In addition, there were no significant differences between two groups in surgical time (MD = −1.83; 95% CI, −4.12 to 0.47; p = 0.12) (Figure 5B).

FIGURE 5

FIGURE 5. Forest plot showing non–bleeding-related outcomes of TXA group vs. control group. (A) Length of hospital stays. (B) Surgical time.

Meta-analysis of thromboembolic events

All studies reported thromboembolic events, which included four hundred and seventy and four hundred and seventy-six patients in the TXA and control groups, respectively). The results of pooled analyses are shown in Figure 6. There were no significant differences between two groups in the incidence of deep vein thrombosis (RR = 1.25; 95% CI, 0.60 to 2.56; p = 0.55) (Figure 6A), pulmonary embolism (RR = 0.85; 95% CI, 0.26 to 2.73; p = 0.78) (Figure 6B), myocardial infarction (RR = 2.06; 95% CI, 0.67 to 6.29; p = 0.21) (Figure 6C), ischemic stroke (RR = 0.59; 95% CI, 0.26 to 1.37; p = 0.22) (Figure 6D).

FIGURE 6

FIGURE 6. Forest plot showing the incidence of thromboembolic events of TXA group vs. control group. (A) Deep vein thrombosis. (B) Pulmonary embolism. (C) Myocardial infarction. (D) Ischemic stroke.

Meta-analysis of other complications

Five studies reported complications after surgery, which included two hundred and ninety-six and two hundred and ninety-eight patients in the TXA and control groups, respectively. The results of pooled analyses are shown in Figure 7. The results showed that the incidence of wound complications in the TXA group was significantly lower than that of the control group (RR = 0.41; 95% CI, 0.18 to 0.91; p = 0.03) (Figure 7A), And there were no significant differences between the two groups in the incidence of respiratory infections (RR = 0.89; 95% CI, 0.43 to 1.81; p = 0.74), renal failure (RR = 0.62; 95% CI, 0.08 to 4.68; p = 0.64) (Figures 7B,C).

FIGURE 7

FIGURE 7. Forest plot showing the incidence of other complications of TXA group vs. control group. (A) Wound complications. (B) Respiratory infection. (C) Renal failure.

Meta-analysis of mortality within 1 year

Eight studies reported postoperative mortality within 1 year, which included four hundred and thirty-three and four hundred and thirty-nine patients in the TXA and control groups, respectively. The results of pooled analyses are shown in Figure 8. The results showed that there were no significant differences between the two groups in postoperative mortality within 1 year (RR = 1.13; 95% CI, 0.71 to 1.80; p = 0.60).

FIGURE 8

FIGURE 8. Forest plot showing the mortality within 1 year of TXA group vs. control group.

Sensitivity analysis

A sensitivity analysis was performed by individually removing each study to determine whether the pooled results changed. No significant heterogeneity of other outcomes was detected, except for bleeding-related outcomes. As for TBL, I² changed from 51 to 22% after one trial (Zhang et al., 2022) excluded from analysis. I² changed from 60 to 0% after one trial (Zhou et al., 2019) excluded from analysis in terms of IBL. I² changed from 62 to 0% after one trial (Zhang et al., 2022) excluded from analysis in terms of HBL. I² changed from 68 to 0% after one trial (Tian et al., 2018) excluded from analysis in terms of POD. I² changed from 52 to 0% after one trial (Lei et al., 2017) excluded from the analysis in terms of postoperative Hb on day 3. There were no statistically significant changes between groups for all bleeding-related outcomes.

Publication bias

The funnel plot of the incidence of deep vein thrombosis showed that the scattered points were roughly symmetrical, suggesting that publication bias among the included studies was mild (Figure 9).

FIGURE 9

FIGURE 9. Funnel plot of the incidence of deep vein thrombosis.

Discussion

In our study, we conducted a systematic review and meta-analysis to investigate the efficacy and safety of TXA in intertrochanteric fracture patients treated with intramedullary fixation. The results showed that the administration of TXA in intertrochanteric fracture patients treated with intramedullary fixation could significantly reduce TBL, IBL, HBL, and BTR, and significantly increased postoperative HB on day 3. In terms of non-bleeding related outcomes, the TXA group can significantly decrease the length of hospital days compared to the control group. In addition, the administration of TXA would not increase the occurrence of thromboembolic events, respiratory infection, renal failure, and postoperative mortality within 1 year. Furthermore, compared to control group, the administration of TXA can significantly decrease the occurrence of wound complications.

Intertrochanteric fractures are common injuries in the frail geriatric population, and often accompanied with high comorbidities, nutritional deficiencies, and chronic wasting disease, which would increase the occurrence of perioperative anemia (Bross et al., 2010; Strøm Rönnquist et al., 2022). In addition, the intertrochanteric region of the femur is mainly consisted of cancellous bone. Once an intertrochanteric fracture occurs, the amount of blood loss can be very large (Xing et al., 2020a; Xing et al., 2021; Xing et al., 2022). To decrease perioperative blood loss in intertrochanteric fracture patients, intramedullary fixation has been widely used as a minimally invasive surgical treatment. The perioperative TBL of intertrochanteric fracture patients consists of visible blood loss and HBL. In addition, the Sahin et al. demonstrated that the amount of HBL in intertrochanteric fracture patients treated with PFNA accounted for the most of the TBL (Sahin et al., 2014). In addition, perioperative blood management methods, such as hemostatic drugs, tourniquets, and autologous blood recovery, have been applied in surgery of intertrochanteric fracture to reduce intraoperative blood loss (Wong et al., 2021). Allogeneic blood transfusion is another useful method for perioperative control of blood loss. However, allogeneic blood transfusion has disadvantages of viral infection, transfusion reaction, and electrolyte imbalance (Raman et al., 2019).

In recent years, more and more researchers utilized TXA as a promising therapy for perioperative blood control. Transient activation of the fibrinolytic cascade during surgery is one of the reasons for high perioperative blood loss (Banach et al., 2022). TXA can prevent fibrinolysis by blocking the lysine-binding site of plasminogen bound to fibrin and displacing plasminogen from the surface of fibrin (Tanaka et al., 2001). Currently, TXA has been widely used in surgical procedures such as cardiothoracic surgery, neurosurgery, and obstetrics (Yu et al., 2022). In the field of orthopedics, TXA exhibit a high effectiveness in reducing perioperative blood loss in spinal fusion surgery and joint replacement surgery (Ling et al., 2021). However, in the field of trauma orthopedics, the efficacy and safety of TXA in fracture surgery still needs to be further investigated.

Our systematic review and meta-analysis demonstrated that TXA could reduce TBL, IBL, and HBL in intertrochanteric fracture patients treated with intramedullary fixation. Recently, more and more clinicians have recognized the existence of HBL during the hip fracture surgery (Sehat et al., 2000). Previous studies found that HBL can even reach up to 1,473 ml during hip fracture surgery (Foss and Kehlet, 2006). In addition, in the minimally invasive surgery of intertrochanteric fractures, the amount of TBL is also large, and accounts for the vast majority of TBL. Sahin et al. found that the perioperative HBL of PFNA surgery was higher than that of surgery of dynamic condylar screws when dealing with intertrochanteric fractures (Sahin et al., 2014).

The previous study found that TBL was significantly higher in the intramedullary fixation group than in the extramedullary fixation group when dealing with elderly patients with intertrochanteric fractures (Cai et al., 2016). The large amount of HBL in intertrochanteric fractures can be attributed to intraoperative dilation of the medullary cavity, traumatic fibrinolytic hyperlysis, and persistent postoperative bleeding (Smith et al., 2011; Bao et al., 2013). In our study, no significant differences were found between TXA group and control group in terms of POD. BTR is an important factor related with fracture prognosis. Our study found that the administration of TXA can significantly decrease BTR in intertrochanteric fracture patients. The previous study showed that perioperative allogeneic blood transfusions is associated with an increased risk of surgical site infection, urinary tract infection, and overall postoperative infection (Janssen et al., 2015). In addition, the reduced BTR is beneficial in lowing risk of transfusion-related disease and hospitalization costs. In our study, no significant differences were observed in postoperative Hb on day 1 and postoperative Hct on day 1 between the TXA group and control group. The postoperative Hb on day 3 of the TXA group was significantly higher than that of the control group. In our opinions, the higher postoperative Hb of control group might be related to the time-effectiveness of the administration of TXA, which needs further research in future. Based on the results of our study, our study demonstrated that the administration of TXA is effective in reducing blood loss and transfusion rate when dealing with patients with intertrochanteric fractures treated with intramedullary fixation. In terms of non-bleeding-related outcomes, our study showed that the length of hospital stays was significantly shorter in the TXA group compared with the control group. In addition, no significant differences were observed in surgical time between the TXA group and control group. In our opinions, the shorter hospital stays mean the lower patient costs and the lower risk of nosocomial infections.

The incidence of thromboembolic events is an important safe indicator when using TXA in intertrochanteric fracture patients. Whether TXA wound increase the incidence of perioperative thromboembolic events still remains unclear. The previous studies showed that TXA did not increase the risk of thromboembolic events in joint replacement surgery and lumbar fusion (Lu et al., 2018; Ling et al., 2021). However, the activated coagulation system, high age, and various comorbidities of intertrochanteric fracture patients can increase the occurrence of thromboembolic events (Xing et al., 2018). The multicenter RCT based on more than twenty thousand trauma patients demonstrated that the administration of TXA did not increase the risk of thromboembolic events (Shakur et al., 2010). Our study showed that the administration of TXA in patients with intertrochanteric fractures treated with intramedullary fixation did not increase the incidence of deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke, which is similar to previous meta-analyses (Xing et al., 2020b; Luo et al., 2020; Li et al., 2021). In our opinions, TXA can reduce blood loss by inactivating the fibrinolytic system rather than by activating the coagulation cascade. However, we also found that some of the included studies did not screen all patients for postoperative thromboembolic events but only after the emergence of relevant clinical symptoms (Drakos et al., 2016; Tengberg et al., 2016; Zhou et al., 2019; Yee et al., 2022). In our opinions, routine postoperative ultrasonography examination is recommended for early detection and diagnosis of thromboembolic events.

Our study also found that the administration of TXA significantly reduced the incidence of wound complications and did not increase the risk of respiratory infection and renal failure. In addition, no significant differences were observed in postoperative mortality within 1 year between TXA group and control group. The main reasons of high mortality rate in the elderly patients with intertrochanteric fractures are various complications such as respiratory infection, lower extremity deep vein thrombosis, and pressure ulcers (Fan et al., 2021). Our study demonstrated that the administration of TXA did not increase the risk of the complications. In addition, among all enrolled studies, four studies conducted surgery within 48 h (Drakos et al., 2016; Tengberg et al., 2016; Schiavone et al., 2018; Yee et al., 2022). The previous study demonstrated that early surgery could reduce the incidence of complications and patient mortality (Pincus et al., 2017). Based on the results of our study, we believe that the administration of TXA is a relatively safe treatment for patients with intertrochanteric fractures treated with intramedullary fixation.

Currently, there is no consensus about the route, dose, and time of administration of TXA in orthopedic surgery (Todeschini et al., 2020). The advantages of topical administration of TXA included maximum concentration at the bleeding site and minimal systemic absorption, thereby reducing the risk of thromboembolic complications and other potential risks (Alshryda et al., 2014). However, another study show no significant differences of local administration of TXA in reducing blood loss and transfusion rates after intertrochanteric fracture surgery (Virani et al., 2016). Dose and time of administration also varied among enrolled studies. Therefore, it is necessary to investigate the optimal route, dose, and time of TXA administrations in the future.

There are several limitations in our study. Firstly, our study is only for patients with intertrochanteric fractures treated with intramedullary fixation, including usual implants such as PFNA and Gamma nails. Secondly, this study included recently published RCTs that reported more outcomes, including bleeding-related outcomes, non-bleeding-related outcomes, thromboembolic events, other complications, and mortality, but the number of included RCTs and the sample size are still small. Thirdly, the follow-up period for the included studies was relatively short. Finally, most of the included studies were conducted in China, and there may be geographical bias.

Conclusion

This systematic review demonstrated that the administration of TXA was an effective and safe drug for perioperative control of blood loss in patients with intertrochanteric fractures treated with intramedullary fixation. In addition, the administration of TXA did not increase the risk of thromboembolic events such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke. Moreover, the administration of TXA significantly reduced the incidence of wound complications, with no effect on the incidence of respiratory infection and renal failure, and postoperative mortality within 1 year. However, the long-term adverse effects of TXA need to be further investigated.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

JJ and FX contributed equally to this study. JJ contributed to search the database, extract the data, analyze the data and manuscript writing. FX helped to extract the data and review the manuscript. RL, MZ, and JX searched the database and extracted the data. XD designed this systematic review. XD and ZX is the correspondence author who responsible for the correspondence, topic identification and manuscript reviewing.

Funding

This work was supported by the National Natural Science Foundation of China (31870961), the International Cooperation Project of the Science and Technology Department of Sichuan Province (Grant No. 2022YFS0099) and Clinical Research Incubation project of West China Hospital of Sichuan University (2019HXFH041).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Alshryda, S., Sukeik, M., Sarda, P., Blenkinsopp, J., Haddad, F. S., and Mason, J. M. (2014). A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Jt. J. 96-b (8), 1005–1015. doi:10.1302/0301-620X.96B8.33745

PubMed Abstract | CrossRef Full Text | Google Scholar

Banach, L., Janczewski, L., Kajdanek, J., Milowska, K., Kolodziejczyk-Czepas, J., Galita, G., et al. (2022). Synthesis and hemostatic activity of new amide derivatives. Mol. (Basel, Switz. 27 (7), 2271. doi:10.3390/molecules27072271

CrossRef Full Text | Google Scholar

Bao, N., Zhou, L., Cong, Y., Guo, T., Fan, W., Chang, Z., et al. (2013). Free fatty acids are responsible for the hidden blood loss in total hip and knee arthroplasty. Med. Hypotheses 81 (1), 104–107. doi:10.1016/j.mehy.2013.03.038

PubMed Abstract | CrossRef Full Text | Google Scholar

Bross, M. H., Soch, K., and Smith-Knuppel, T. (2010). Anemia in older persons. Am. Fam. Physician 82 (5), 480–487.

PubMed Abstract | Google Scholar

Cai, L., Wang, T., Di, L., Hu, W., and Wang, J. (2016). Comparison of intramedullary and extramedullary fixation of stable intertrochanteric fractures in the elderly: A prospective randomised controlled trial exploring hidden perioperative blood loss. BMC Musculoskelet. Disord. 17 (1), 475. doi:10.1186/s12891-016-1333-z

PubMed Abstract | CrossRef Full Text | Google Scholar

Carvalho, L. H., Frois Temponi, E., Machado Soares, L. F., Gonçalves, M. B., Paiva Costa, L., and Tavares de Souza, M. L. (2015). Bleeding reduction after topical application of tranexamic acid together with Betadine solution in total knee arthroplasty. A randomised controlled study. Orthop. Traumatol. Surg. Res. 101 (1), 83–87. doi:10.1016/j.otsr.2014.10.013

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, Y., Zhu, J., Zhou, Y., Peng, J., and Wang, B. (2021). Efficacy and safety of denosumab in osteoporosis or low bone mineral density postmenopausal women. Front. Pharmacol. 12. 588095. doi:10.3389/fphar.2021.588095

PubMed Abstract | CrossRef Full Text | Google Scholar

Cheng, S. Y., Levy, A. R., Lefaivre, K. A., Guy, P., Kuramoto, L., and Sobolev, B. (2011). Geographic trends in incidence of hip fractures: A comprehensive literature review. Osteoporos. Int. 22 (10), 2575–2586. doi:10.1007/s00198-011-1596-z

PubMed Abstract | CrossRef Full Text | Google Scholar

Cooper, C., Campion, G., and Melton, L. J. (1992). Hip fractures in the elderly: A world-wide projection. Osteoporos. Int. 2 (6), 285–289. doi:10.1007/BF01623184

PubMed Abstract | CrossRef Full Text | Google Scholar

Corbett, M. S., Higgins, J. P., and Woolacott, N. F. (2014). Assessing baseline imbalance in randomised trials: Implications for the Cochrane risk of bias tool. Res. Synth. Methods 5 (1), 79–85. doi:10.1002/jrsm.1090

PubMed Abstract | CrossRef Full Text | Google Scholar

Dehghan, N., and McKee, M. D. (2020). What's new in orthopaedic trauma. J. Bone Jt. Surg. Am. 102 (13), 1137–1141. doi:10.2106/JBJS.20.00425

CrossRef Full Text | Google Scholar

Drakos, A., Raoulis, V., Karatzios, K., Doxariotis, N., Kontogeorgakos, V., Malizos, K., et al. (2016). Efficacy of local administration of tranexamic acid for blood salvage in patients undergoing intertrochanteric fracture surgery. J. Orthop. Trauma 30 (8), 409–414. doi:10.1097/BOT.0000000000000577

PubMed Abstract | CrossRef Full Text | Google Scholar

Eriksen, M. B., and Frandsen, T. F. (2018). The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: A systematic review. J. Med. Libr. Assoc. 106 (4), 420–431. doi:10.5195/jmla.2018.345

PubMed Abstract | CrossRef Full Text | Google Scholar

Fan, J., Lv, Y., Xu, X., Zhou, F., Zhang, Z., Tian, Y., et al. (2021). The efficacy of multidisciplinary team Co-management program for elderly patients with intertrochanteric fractures: A retrospective study. Front. Surg. 8, 816763. doi:10.3389/fsurg.2021.816763

PubMed Abstract | CrossRef Full Text | Google Scholar

Foss, N. B., and Kehlet, H. (2006). Hidden blood loss after surgery for hip fracture. J. Bone Jt. Surg. Br. 88 (8), 1053–1059. doi:10.1302/0301-620X.88B8.17534

PubMed Abstract | CrossRef Full Text | Google Scholar

Hartland, A. W., Teoh, K. H., and Rashid, M. S. (2021). Clinical effectiveness of intraoperative tranexamic acid use in shoulder surgery: A systematic review and meta-analysis. Am. J. Sports Med. 49 (11), 3145–3154. doi:10.1177/0363546520981679

PubMed Abstract | CrossRef Full Text | Google Scholar

Higgins, J. P. T., and Green, S. (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0. London, United Kingdom: The Cochrane Collaboration. http://handbook.cochrane.org/.

PubMed Abstract | Google Scholar

Janssen, S. J., Braun, Y., Wood, K. B., Cha, T. D., and Schwab, J. H. (2015). Allogeneic blood transfusions and postoperative infections after lumbar spine surgery. Spine J. 15 (5), 901–909. doi:10.1016/j.spinee.2015.02.010

PubMed Abstract | CrossRef Full Text | Google Scholar

Jiang, J., Xing, F., Luo, R., and Liu, M. (2022). Effectiveness of platelet-rich plasma for patients with carpal tunnel syndrome: A systematic review and meta-analysis of current evidence in randomized controlled trials. Front. Pharmacol. 13, 834213. doi:10.3389/fphar.2022.834213

PubMed Abstract | CrossRef Full Text | Google Scholar

Lei, J., Zhang, B., Cong, Y., Zhuang, Y., Wei, X., Fu, Y., et al. (2017). Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: A single-center randomized controlled trial. J. Orthop. Surg. Res. 12 (1), 124. doi:10.1186/s13018-017-0625-9

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, S., Xing, F., Cen, Y., and Zhang, Z. (2021). The efficacy and safety of epsilon-aminocaproic acid for perioperative blood management in spinal fusion surgery: A systematic review and meta-analysis. World Neurosurg. 156, 12–21. doi:10.1016/j.wneu.2021.08.113

PubMed Abstract | CrossRef Full Text | Google Scholar

Ling, T., Zhao, Z., Xu, W., Ge, W., and Huang, L. (2021). Effects of tranexamic acid on hemorrhage control and deep venous thrombosis rate after total knee arthroplasty: A systematic review and network meta-analysis of randomized controlled trials. Front. Pharmacol. 12, 639694. doi:10.3389/fphar.2021.639694

PubMed Abstract | CrossRef Full Text | Google Scholar

Ljungqvist, O., Scott, M., and Fearon, K. C. (2017). Enhanced recovery after surgery: A review. JAMA Surg. 152 (3), 292–298. doi:10.1001/jamasurg.2016.4952

PubMed Abstract | CrossRef Full Text | Google Scholar

Lu, V. M., Ho, Y. T., Nambiar, M., Mobbs, R. J., and Phan, K. (2018). The perioperative efficacy and safety of antifibrinolytics in adult spinal fusion surgery: A systematic review and meta-analysis. Spine 43 (16), E949–e958. doi:10.1097/BRS.0000000000002580

PubMed Abstract | CrossRef Full Text | Google Scholar

Luo, X., He, S., Lin, Z., Li, Z., Huang, C., and Li, Q. (2019). Efficacy and safety of tranexamic acid for controlling bleeding during surgical treatment of intertrochanteric fragility fracture with proximal femoral nail anti-rotation: A randomized controlled trial. Indian J. Orthop. 53 (2), 263–269. doi:10.4103/ortho.IJOrtho_401_17

PubMed Abstract | CrossRef Full Text | Google Scholar

Luo, X., Huang, H., and Tang, X. (2020). Efficacy and safety of tranexamic acid for reducing blood loss in elderly patients with intertrochanteric fracture treated with intramedullary fixation surgery: A meta-analysis of randomized controlled trials. Acta Orthop. Traumatol. Turc. 54 (1), 4–14. doi:10.5152/j.aott.2020.01.88

PubMed Abstract | CrossRef Full Text | Google Scholar

Milto, A. J., El Bitar, Y., Scaife, S. L., and Thuppal, S. (2022). Differences in hospital length of stay and total hospital charge by income level in patients hospitalized for hip fractures. Osteoporos. Int. 33 (5), 1067–1078. doi:10.1007/s00198-021-06260-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Pabinger, I., Fries, D., Schöchl, H., Streif, W., and Toller, W. (2017). Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien. Klin. Wochenschr. 129 (9-10), 303–316. doi:10.1007/s00508-017-1194-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Pincus, D., Ravi, B., Wasserstein, D., Huang, A., Paterson, J. M., Nathens, A. B., et al. (2017). Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. Jama 318 (20), 1994–2003. doi:10.1001/jama.2017.17606

PubMed Abstract | CrossRef Full Text | Google Scholar

Porter, S. B., Spaulding, A. C., Duncan, C. M., Wilke, B. K., Pagnano, M. W., and Abdel, M. P. (2022). Tranexamic acid was not associated with increased complications in high-risk patients with intertrochanteric fracture. J. Bone Jt. Surg. 104 (13), 1138–1147. doi:10.2106/jbjs.21.01389

CrossRef Full Text | Google Scholar

Raman, T., Varlotta, C., Vasquez-Montes, D., Buckland, A. J., and Errico, T. J. (2019). The use of tranexamic acid in adult spinal deformity: Is there an optimal dosing strategy? Spine J. 19 (10), 1690–1697. doi:10.1016/j.spinee.2019.06.012

PubMed Abstract | CrossRef Full Text | Google Scholar

Sahin, E. K., Imerci, A., Kınık, H., Karapınar, L., Canbek, U., and Savran, A. (2014). Comparison of proximal femoral nail antirotation (PFNA) with AO dynamic condylar screws (DCS) for the treatment for unstable peritrochanteric femoral fractures. Eur. J. Orthop. Surg. Traumatol. 24 (3), 347–352. doi:10.1007/s00590-013-1195-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Schiavone, A., Bisaccia, M., Inkov, I., Rinonapoli, G., Manni, M., Rollo, G., et al. (2018). Tranexamic acid in pertrochanteric femoral fracture: Is it a safe drug or not? Folia Med. 60 (1), 67–78. doi:10.1515/folmed-2017-0070

PubMed Abstract | CrossRef Full Text | Google Scholar

Sehat, K. R., Evans, R., and Newman, J. H. (2000). How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. Knee 7 (3), 151–155. doi:10.1016/s0968-0160(00)00047-8

PubMed Abstract | CrossRef Full Text | Google Scholar

Shakur, H., Roberts, I., Bautista, R., Caballero, J., Coats, T., Dewan, Y., et al. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet (London, Engl. 376 (9734), 23–32. doi:10.1016/S0140-6736(10)60835-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Smith, G. H., Tsang, J., Molyneux, S. G., and White, T. O. (2011). The hidden blood loss after hip fracture. Injury 42 (2), 133–135. doi:10.1016/j.injury.2010.02.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Strøm Rönnquist, S., Viberg, B., Kristensen, M. T., Palm, H., Jensen, J. B., Madsen, C. F., et al. (2022). Frailty and osteoporosis in patients with hip fractures under the age of 60-a prospective cohort of 218 individuals. Osteoporos. Int. 33 (5), 1037–1055. doi:10.1007/s00198-021-06281-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Tanaka, N., Sakahashi, H., Sato, E., Hirose, K., Ishima, T., and Ishii, S. (2001). Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J. Bone Jt. Surg. Br. 83 (5), 702–705. doi:10.1302/0301-620x.83b5.11745

PubMed Abstract | CrossRef Full Text | Google Scholar

Tang, P., Hu, F., Shen, J., Zhang, L., and Zhang, L. (2012). Proximal femoral nail antirotation versus hemiarthroplasty: A study for the treatment of intertrochanteric fractures. Injury 43 (6), 876–881. doi:10.1016/j.injury.2011.11.008

PubMed Abstract | CrossRef Full Text | Google Scholar

Tengberg, P. T., Foss, N. B., Palm, H., Kallemose, T., and Troelsen, A. (2016). Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: Results of a randomised controlled trial. Bone Jt. J. 98-b (6), 747–753. doi:10.1302/0301-620X.98B6.36645

PubMed Abstract | CrossRef Full Text | Google Scholar

Tian, S., Shen, Z., Liu, Y., Zhang, Y., and Peng, A. (2018). The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury 49 (3), 680–684. doi:10.1016/j.injury.2018.01.026

PubMed Abstract | CrossRef Full Text | Google Scholar

Todeschini, A. B., Uribe, A. A., Echeverria-Villalobos, M., Fiorda-Diaz, J., Abdel-Rasoul, M., McGahan, B. G., et al. (2020). Efficacy of intravenous tranexamic acid in reducing perioperative blood loss and blood product transfusion requirements in patients undergoing multilevel thoracic and lumbar spinal surgeries: A retrospective study. Front. Pharmacol. 11, 566956. doi:10.3389/fphar.2020.566956

PubMed Abstract | CrossRef Full Text | Google Scholar

Virani, S. R., Dahapute, A. A., Panda, I., and Bava, S. S. (2016). Role of local infiltration of tranexamic acid in reducing blood loss in peritrochanteric fracture surgery in the elderly population. Malays. Orthop. J. 10 (3), 26–30. doi:10.5704/MOJ.1611.013

PubMed Abstract | CrossRef Full Text | Google Scholar

Vochteloo, A. J., Borger van der Burg, B. L., Mertens, B., Niggebrugge, A. H., de Vries, M. R., Tuinebreijer, W. E., et al. (2011). Outcome in hip fracture patients related to anemia at admission and allogeneic blood transfusion: An analysis of 1262 surgically treated patients. BMC Musculoskelet. Disord. 12, 262. doi:10.1186/1471-2474-12-262

PubMed Abstract | CrossRef Full Text | Google Scholar

Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14, 135. doi:10.1186/1471-2288-14-135

PubMed Abstract | CrossRef Full Text | Google Scholar

Wong, J., George, R. B., Hanley, C. M., Saliba, C., Yee, D. A., and Jerath, A. (2021). Tranexamic acid: Current use in obstetrics, major orthopedic, and trauma surgery. Can. J. Anaesth. = J. Can. d'anesthesie 68 (6), 894–917. doi:10.1007/s12630-021-01967-7

CrossRef Full Text | Google Scholar

Xing, F., Chen, W., Long, C., Huang, F., Wang, G., and Xiang, Z. (2020). Postoperative outcomes of tranexamic acid use in geriatric trauma patients treated with proximal femoral intramedullary nails: A systematic review and meta-analysis. Orthop. Traumatol. Surg. Res. 106 (1), 117–126. doi:10.1016/j.otsr.2019.10.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Xing, F., Li, L., Chen, W., and Xiang, Z. (2020). The effect of Parkinson's disease on Chinese geriatric patients with intertrochanteric fracture: A propensity score-matched analysis. Orthop. Traumatol. Surg. Res. 106 (4), 627–632. doi:10.1016/j.otsr.2019.11.022

PubMed Abstract | CrossRef Full Text | Google Scholar

Xing, F., Li, L., Long, Y., and Xiang, Z. (2018). Admission prevalence of deep vein thrombosis in elderly Chinese patients with hip fracture and a new predictor based on risk factors for thrombosis screening. BMC Musculoskelet. Disord. 19 (1), 444. doi:10.1186/s12891-018-2371-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Xing, F., Luo, R., Chen, W., and Zhou, X. (2021). The risk-adjusted Charlson comorbidity index as a new predictor of one-year mortality rate in elderly Chinese patients who underwent hip fracture surgery. Orthop. Traumatol. Surg. Res. 107 (3), 102860. doi:10.1016/j.otsr.2021.102860

PubMed Abstract | CrossRef Full Text | Google Scholar

Xing, F., Luo, R., Liu, M., Zhou, Z., Xiang, Z., and Duan, X. (2022). A new random forest algorithm-based prediction model of post-operative mortality in geriatric patients with hip fractures. Front. Med. 9, 829977. doi:10.3389/fmed.2022.829977

CrossRef Full Text | Google Scholar

Yee, D. K., Wong, J. S. H., Fang, E., Wong, T. M., Fang, C., and Leung, F. (2022). Topical administration of tranexamic acid in elderly patients undergoing short femoral nailing for intertrochanteric fracture: A randomised controlled trial. Injury 53 (2), 603–609. doi:10.1016/j.injury.2021.11.055

PubMed Abstract | CrossRef Full Text | Google Scholar

Yu, W., Chen, W., Jiang, Y., Ma, M., Zhang, W., Zhang, X., et al. (2022). Effectiveness comparisons of drug therapy on chronic subdural hematoma recurrence: A bayesian network meta-analysis and systematic review. Front. Pharmacol. 13, 845386. doi:10.3389/fphar.2022.845386

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, S., Xiao, C., Yu, W., Long, N., He, F., Cai, P., et al. (2022). Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: A randomized controlled trial. Eur. J. Trauma Emerg. Surg. 48 (2), 731–741. doi:10.1007/s00068-020-01387-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, X. D., Zhang, Y., Jiang, L. F., Zhang, J. J., Zhou, D., Wu, L. D., et al. (2019). Efficacy and safety of tranexamic acid in intertrochanteric fractures: A single-blind randomized controlled trial. Orthop. Surg. 11 (4), 635–642. doi:10.1111/os.12511

PubMed Abstract | CrossRef Full Text | Google Scholar